Research Activity
Cancer Pipelines Contract: Incyte and iTeos Discontinue Drug Candidates Amid Underwhelming Clinical Results
Incyte, iTeos, cancer pipelines, drug candidates, clinical trials, disappointing data, pipeline cuts, oncology research.
SIGA’s TPOXX Fails to Demonstrate Efficacy in Treating Mild to Moderate Mpox Cases: STOMP Study Results
SIGA Technologies, TPOXX, Tecovirimat, Mpox, STOMP Study, Antiviral Treatment, Efficacy, Safety Profile
Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial
Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval
Relay Therapeutics Advances PI3K Inhibitor for Breast Cancer Subgroup with Promising Early Trial Results
Relay Therapeutics, PI3K inhibitor, breast cancer, RLY-2608, metastatic breast cancer, PI3Ka mutations, clinical trial
Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks
Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO
BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission
BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany
BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results
BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies
Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials
Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)
GSK and Relation Therapeutics Collaborate on Fibrosis and Osteoarthritis Research with AI-Driven Approach
Relation Therapeutics, GSK, Fibrosis, Osteoarthritis, AI in drug discovery, Machine learning in biotech
Belharra Therapeutics Reduces Workforce by 40%, Laying Off 21 Employees
Belharra Therapeutics, layoffs, workforce reduction, biotech industry, drug discovery